Trial Profile
Effort of canagliflozin on metabolic syndrome parameters and biomarkers of heart, kidney and vascular diseases in patients with type 2 diabetes mellitus.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2018
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 11 May 2018 Status changed from recruiting to completed.
- 07 Jul 2015 New trial record